The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

The following is a summary of “Incidence of Pneumocystis jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among ...

Although most experts advise that such patients receive CMV prophylaxis, CMV disease often develops shortly after stopping a 3-month course of antiviral prophylaxis (often between 3 and 6 months ...

Purpose: The implications of recent studies for guidelines that pertain to stress ulcer prophylaxis in the postoperative period are discussed. Summary: The therapeutic guidelines on stress ulcer ...

Background The use of quinolone prophylaxis in high-risk neutropenic patients is considered standard of care but the development of resistance is a concern. Previous studies have focused mainly on ...

A PHASE 3 clinical trial, explorer8, has demonstrated the efficacy and safety of concizumab, a monoclonal antibody in ...

Historically, sickle cell anaemia has been widely neglected within its global epicentre of sub-Saharan Africa. More than ...

A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...

Thanks to the introduction of new monoclonal antibodies and vaccines. The respiratory syncytial virus (RSV) prophylaxis ...

12 In this meeting, the combination of nonselective β-blockers and EBL was accepted to probably be the best treatment for the prophylaxis of variceal rebleeding. In addition, this recommendation ...

The lead program from this biotech is CD388 as a DFC, which is being explored in the ongoing phase 2b NAVIGATE trial as a prophylaxis for influenza. Why should investors care about this company ...